Tevogen Bio Holdings Inc. (TVGN)Healthcare | Biotechnology | Warren, United States | NasdaqGM
10.47 USD
-1.20
(-10.283%) ⇩
(June 12, 2026, 4 p.m.
EDT)
After hours: 10.26 -0.21 (-0.210%) ⇩ (June 12, 2026, 4:59 p.m. EDT) |
Hot Take ↕ | June 7, 2026, 4:46 a.m. EDT
The immediate outlook is severely clouded by a massive statistical forecast leaning negative (-4.77%) combined with a chaotic recent price pattern where the stock surged to $11.56 before collapsing back to the $8-$9 range. While the company recently secured financing and management claims to have cut losses, the balance sheet remains critically impaired with negative book value, a current ratio of 0.295, and significant debt obligations that dwarf cash reserves. This creates a precarious liquidity situation where the market is likely pricing in an imminent delisting or further distress, overriding any potential strategic pivots mentioned in recent headlines. From a long-term perspective, the investment case is equally weak; despite a recent year-over-year price recovery, the underlying business has suffered a catastrophic -92% decline over the last three years, indicating a fundamental failure to generate sustainable value. With no dividend history and a history of massive share price erosion, this is a speculative gamble rather than an investment. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.314106 |
| AutoETS | 0.318023 |
| MSTL | 0.334535 |
| AutoTheta | 0.784244 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 6.05 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.371 |
| Excess Kurtosis | -0.86 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 43,843,180 |
| Beta | 0.16 |
| Previous Name | Semper Paratus Acquisition Corporation |
| Website | https://tevogen.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.8351181 |
| Address1 | 15 Independence Boulevard |
| Address2 | Suite #210 |
| All Time High | 1,054.5 |
| All Time Low | 4.135 |
| Ask | 13.38 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Daily Volume10 Day | 30,920 |
| Average Daily Volume3 Month | 32,161 |
| Average Volume | 32,161 |
| Average Volume10Days | 30,920 |
| Beta | 0.161 |
| Bid | 8.61 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | -4.237 |
| City | Warren |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 10.47 |
| Current Ratio | 0.295 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,780,012,800 |
| Day High | 12.0 |
| Day Low | 9.92 |
| Display Name | Tevogen Bio |
| Earnings Timestamp End | 1,786,651,200 |
| Earnings Timestamp Start | 1,786,651,200 |
| Ebitda | -21,004,800 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.924 |
| Enterprise Value | 61,423,572 |
| Eps Trailing Twelve Months | -6.44 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.8904 |
| Fifty Day Average Change | 2.5796003 |
| Fifty Day Average Change Percent | 0.32692897 |
| Fifty Two Week Change Percent | -83.51181 |
| Fifty Two Week High | 71.0 |
| Fifty Two Week High Change | -60.53 |
| Fifty Two Week High Change Percent | -0.8525352 |
| Fifty Two Week Low | 4.135 |
| Fifty Two Week Low Change | 6.335 |
| Fifty Two Week Low Change Percent | 1.5320435 |
| Fifty Two Week Range | 4.135 - 71.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,641,393,000,000 |
| Float Shares | 1,074,053 |
| Free Cashflow | -3,168,028 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 18 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,780,531,200 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.74408996 |
| Held Percent Institutions | 0.03619 |
| Implied Shares Outstanding | 4,187,505 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,772,755,200 |
| Last Split Factor | 1:50 |
| Long Business Summary | Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey. |
| Long Name | Tevogen Bio Holdings Inc. |
| Market | us_market |
| Market Cap | 43,843,180 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_702249906 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-06-12 |
| Net Income To Common | -21,942,570 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 48,868,183 |
| Open | 12.0 |
| Operating Cashflow | -11,754,283 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 877 838 6434 |
| Post Market Change | -0.21000004 |
| Post Market Change Percent | -2.0057309 |
| Post Market Price | 10.26 |
| Post Market Time | 1,781,297,993 |
| Prev Name | Semper Paratus Acquisition Corporation |
| Previous Close | 11.67 |
| Price Hint | 2 |
| Price To Book | -2.4710882 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.117 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -1.2 |
| Regular Market Change Percent | -10.2828 |
| Regular Market Day High | 12.0 |
| Regular Market Day Low | 9.92 |
| Regular Market Day Range | 9.92 - 12.0 |
| Regular Market Open | 12.0 |
| Regular Market Previous Close | 11.67 |
| Regular Market Price | 10.47 |
| Regular Market Time | 1,781,294,400 |
| Regular Market Volume | 23,002 |
| Return On Assets | -2.9442801 |
| Sand P52 Week Change | 0.23177934 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 4,187,505 |
| Shares Percent Shares Out | 0.025999999 |
| Shares Short | 108,916 |
| Shares Short Previous Month Date | 1,777,507,200 |
| Shares Short Prior Month | 106,924 |
| Short Name | Tevogen Bio Holdings Inc. |
| Short Percent Of Float | 0.0721 |
| Short Ratio | 3.13 |
| Source Interval | 15 |
| State | NJ |
| Symbol | TVGN |
| Total Cash | 692,305 |
| Total Cash Per Share | 0.165 |
| Total Debt | 9,472,709 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -6.44 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 19.131676 |
| Two Hundred Day Average Change | -8.661675 |
| Two Hundred Day Average Change Percent | -0.45274004 |
| Type Disp | Equity |
| Volume | 23,002 |
| Website | https://tevogen.com |
| Zip | 7,059 |